We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


12 March 2007 By Una Galani

The US drugs group is paying E11bn for Organon Biosciences that’s well above what Azko’s pharma unit was expected to fetch in an IPO. The deal just about stacks up financially for Schering. Meanwhile Akzo now has the firepower to bid for ICI.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)